INT203617

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.74
First Reported 2006
Last Reported 2010
Negated 0
Speculated 2
Reported most in Body
Documents 9
Total Number 11
Disease Relevance 4.36
Pain Relevance 0.10

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

extracellular space (F8) oxidoreductase activity (F8) extracellular region (F8)
cell adhesion (F8) plasma membrane (F8)
Anatomy Link Frequency
blood 1
endothelial cells 1
vessels 1
pericytes 1
platelets 1
F8 (Homo sapiens)
Pain Link Frequency Relevance Heat
tolerance 7 80.12 Quite High
cytokine 4 50.12 Quite High
chemokine 3 48.84 Quite Low
metalloproteinase 16 46.92 Quite Low
Inflammation 21 35.72 Quite Low
withdrawal 6 30.96 Quite Low
cva 17 5.00 Very Low Very Low Very Low
COX-2 inhibitor 6 5.00 Very Low Very Low Very Low
corticosteroid 5 5.00 Very Low Very Low Very Low
Pain 5 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Injury 32 99.78 Very High Very High Very High
Pulmonary Disease 52 98.84 Very High Very High Very High
Hemorrhage 126 98.44 Very High Very High Very High
Coagulation Disorder 286 98.40 Very High Very High Very High
Asthma 57 88.80 High High
Body Weight 3 85.04 High High
Hypersensitivity 5 84.20 Quite High
Cancer 49 83.24 Quite High
Increased Venous Pressure Under Development 17 82.72 Quite High
Acquired Immune Deficiency Syndrome Or Hiv Infection 4 80.72 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
This was probably due to recruitment of platelets to the sites of injury and local release of FVIII from activated platelets at wound sites.59

Summary

Localization (release) of FVIII in platelets associated with injury
1) Confidence 0.74 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.61 Pain Relevance 0
The combined results of the phase I and II clinical studies described above show that PEGLip-FVIII is well tolerated and provides extended protection from bleeding following prophylactic treatment.


Localization (tolerated) of PEGLip-FVIII associated with hemorrhage
2) Confidence 0.69 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.37 Pain Relevance 0
In this study, we designed an hGH-loaded dex-HEMA microsphere formulation which releases the protein for 7 days.
Localization (releases) of HEMA
3) Confidence 0.68 Published 2007 Journal Pharm Res Section Body Doc Link PMC2063566 Disease Relevance 0.09 Pain Relevance 0
History of pathogen transmission and the need for blood-free recombinant FVIII technology
Localization (technology) of FVIII in blood
4) Confidence 0.65 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2291300 Disease Relevance 0.83 Pain Relevance 0.08
In this article we present a new platform technology that produces long-acting forms of FVIII and FVIIa and improves the efficacy of hemophilia treatment.
Localization (forms) of FVIII associated with coagulation disorder
5) Confidence 0.65 Published 2010 Journal Int J Nanomedicine Section Abstract Doc Link PMC2939703 Disease Relevance 0.40 Pain Relevance 0
The study showed that PEGLip-FVIII may be administered at an infusion rate similar to that of standard FVIII.54
Localization (administered) of PEGLip-FVIII
6) Confidence 0.60 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.39 Pain Relevance 0
The study showed that PEGLip-FVIII may be administered at an infusion rate similar to that of standard FVIII.54
Localization (administered) of FVIII
7) Confidence 0.60 Published 2010 Journal Int J Nanomedicine Section Body Doc Link PMC2939703 Disease Relevance 0.40 Pain Relevance 0
Vascularization was determined by immunolocalization of factor VIII (marker of endothelial cells), VEGF (expressed by pericytes and smooth muscle cells), and SMCA (marker of pericytes and smooth muscle cells).
Spec (determined) Localization (immunolocalization) of factor VIII in smooth muscle cells
8) Confidence 0.10 Published 2008 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2323016 Disease Relevance 0 Pain Relevance 0
Notably, the lack of difference in vascularity between COPD and controls in the Kuwano study was probably due to the use of Factor VIII, which is not the gold standard to outline vessels [49].
Localization (use) of Factor VIII in vessels associated with pulmonary disease
9) Confidence 0.09 Published 2010 Journal Respir Res Section Body Doc Link PMC2955663 Disease Relevance 1.06 Pain Relevance 0.03
Vascularization was determined by immunolocalization of factor VIII (marker of endothelial cells), VEGF (expressed by pericytes and smooth muscle cells), and SMCA (marker of pericytes and smooth muscle cells).
Spec (determined) Localization (immunolocalization) of factor VIII in pericytes
10) Confidence 0.03 Published 2008 Journal Reprod Biol Endocrinol Section Body Doc Link PMC2323016 Disease Relevance 0 Pain Relevance 0
Immunohistochemical localization of factor VIII related antigen on endothelial cells was determined using the polyclonal rabbit anti-human Von Willebrand Factor (Dako Cytomation, Carpinteria, CA, USA), using the manufacturers' recommended staining protocol.
Localization (localization) of factor VIII in endothelial cells
11) Confidence 0.03 Published 2006 Journal Breast Cancer Res Section Body Doc Link PMC1797025 Disease Relevance 0.21 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox